# Effectiveness of Rebif® in Clinically Isolated Syndrome and Relapsing Multiple Sclerosis Using RebiSmart™

> **NCT02254304** · PHASE4 · COMPLETED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 106 (actual)

## Conditions studied

- Relapsing Multiple Sclerosis
- Clinically Isolated Syndrome

## Interventions

- **DRUG:** Rebif

## Key facts

- **NCT ID:** NCT02254304
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12-31
- **Primary completion:** 2016-08-20
- **Final completion:** 2016-08-20
- **Target enrollment:** 106 (ACTUAL)
- **Last updated:** 2018-03-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02254304

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02254304, "Effectiveness of Rebif® in Clinically Isolated Syndrome and Relapsing Multiple Sclerosis Using RebiSmart™". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02254304. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*